Startup profile · funding coverage
Abridge
AI medical conversation platform that turns clinician-patient dialogue into structured notes.
Stage
growth
Status
private
Coverage
full
Why Abridge is interesting
Abridge competes in the hot clinical documentation category with strong hospital distribution. Together with Ambience, it maps the “AI scribe” war.
Key facts
- Series C (Feb 2024): $150M co-led by Lightspeed and Redpoint with Spark, USV, Bessemer (Abridge press release)
- Series E (Jun 2025): $300M led by a16z with Khosla Ventures participation (STAT News)
Investors in our directory
Funds linked from Abridge's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Abridge
Funding context and why this company shows up in venture coverage.
Abridge captures medical conversations and auto-generates clinical documentation — an AI scribe that reduces physician charting time in hospital and clinic settings.
Directory-linked investors include Andreessen Horowitz (/fund/andreessen-horowitz), Lightspeed (/fund/lightspeed-venture-partners-nyc), Redpoint Ventures (/fund/redpoint-ventures), Spark Capital (/fund/spark-capital), Union Square Ventures (/fund/union-square-ventures), Bessemer (/fund/bessemer-venture-partners), and Khosla Ventures (/fund/khosla-ventures).
Abridge raised a $150M Series C (Feb 2024) and a reported $300M Series E (Jun 2025) — late-stage private growth.
Clinical documentation is a top physician burnout driver. Abridge is among the leaders landing enterprise hospital contracts in the crowded AI scribe market alongside Ambience and others.
No — Abridge remains private as of July 2026.
Last updated: 2026-07-24